204 related articles for article (PubMed ID: 31283222)
1. Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability.
Ladi E; Everett C; Stivala CE; Daniels BE; Durk MR; Harris SF; Huestis MP; Purkey HE; Staben ST; Augustin M; Blaesse M; Steinbacher S; Eidenschenk C; Pappu R; Siu M
J Med Chem; 2019 Aug; 62(15):7032-7041. PubMed ID: 31283222
[TBL] [Abstract][Full Text] [Related]
2. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
3. Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Kasam V; Lee NR; Kim KB; Zhan CG
Bioorg Med Chem Lett; 2014 Aug; 24(15):3614-7. PubMed ID: 24913713
[TBL] [Abstract][Full Text] [Related]
4. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
[TBL] [Abstract][Full Text] [Related]
7. (Immuno)proteasomes as therapeutic target in acute leukemia.
Cloos J; Roeten MS; Franke NE; van Meerloo J; Zweegman S; Kaspers GJ; Jansen G
Cancer Metastasis Rev; 2017 Dec; 36(4):599-615. PubMed ID: 29071527
[TBL] [Abstract][Full Text] [Related]
8. Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome.
Sosič I; Gobec M; Brus B; Knez D; Živec M; Konc J; Lešnik S; Ogrizek M; Obreza A; Žigon D; Janežič D; Mlinarič-Raščan I; Gobec S
Angew Chem Int Ed Engl; 2016 May; 55(19):5745-8. PubMed ID: 27037901
[TBL] [Abstract][Full Text] [Related]
9. Immunoproteasome-selective inhibitors: the future of autoimmune diseases?
Zhang C; Zhu H; Shao J; He R; Xi J; Zhuang R; Zhang J
Future Med Chem; 2020 Feb; 12(4):269-272. PubMed ID: 31983229
[No Abstract] [Full Text] [Related]
10. The immunoproteasome as a target in hematologic malignancies.
Kuhn DJ; Orlowski RZ
Semin Hematol; 2012 Jul; 49(3):258-62. PubMed ID: 22726549
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.
Pletinckx K; Vaßen S; Schlusche I; Nordhoff S; Bahrenberg G; Dunkern TR
Pharmacol Res Perspect; 2019 Aug; 7(4):e00482. PubMed ID: 31236277
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).
Klein M; Busch M; Friese-Hamim M; Crosignani S; Fuchss T; Musil D; Rohdich F; Sanderson MP; Seenisamy J; Walter-Bausch G; Zanelli U; Hewitt P; Esdar C; Schadt O
J Med Chem; 2021 Jul; 64(14):10230-10245. PubMed ID: 34228444
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of the immunoproteasome: current status and future directions.
Miller Z; Ao L; Kim KB; Lee W
Curr Pharm Des; 2013; 19(22):4140-51. PubMed ID: 23181576
[TBL] [Abstract][Full Text] [Related]
14. Immunoproteasome Activity and Content Determine Hematopoietic Cell Sensitivity to ONX-0914 and to the Infection of Cells with Lentiviruses.
Vagapova E; Burov A; Spasskaya D; Lebedev T; Astakhova T; Spirin P; Prassolov V; Karpov V; Morozov A
Cells; 2021 May; 10(5):. PubMed ID: 34066177
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors.
Kirk CJ; Muchamuel T; Wang J; Fan RA
Cells; 2021 Dec; 11(1):. PubMed ID: 35011570
[TBL] [Abstract][Full Text] [Related]
16. Discovery of selective fragment-sized immunoproteasome inhibitors.
Kollár L; Gobec M; Szilágyi B; Proj M; Knez D; Ábrányi-Balogh P; Petri L; Imre T; Bajusz D; Ferenczy GG; Gobec S; Keserű GM; Sosič I
Eur J Med Chem; 2021 Jul; 219():113455. PubMed ID: 33894528
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Biochemical Evaluation of Warhead-Decorated Psoralens as (Immuno)Proteasome Inhibitors.
Schiffrer ES; Proj M; Gobec M; Rejc L; Šterman A; Mravljak J; Gobec S; Sosič I
Molecules; 2021 Jan; 26(2):. PubMed ID: 33445542
[TBL] [Abstract][Full Text] [Related]
18. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
Besse L; Besse A; Kraus M; Maurits E; Overkleeft HS; Bornhauser B; Bourquin JP; Driessen C
Cells; 2021 Oct; 10(11):. PubMed ID: 34831075
[TBL] [Abstract][Full Text] [Related]
19. A patent review of immunoproteasome inhibitors.
Ogorevc E; Schiffrer ES; Sosič I; Gobec S
Expert Opin Ther Pat; 2018 Jul; 28(7):517-540. PubMed ID: 29865878
[TBL] [Abstract][Full Text] [Related]
20. Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads.
Kollár L; Gobec M; Proj M; Smrdel L; Knez D; Imre T; Gömöry Á; Petri L; Ábrányi-Balogh P; Csányi D; Ferenczy GG; Gobec S; Sosič I; Keserű GM
Cells; 2021 Dec; 10(12):. PubMed ID: 34943940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
